Latest Breaking News On - Lewis dexter - Page 1 : comparemela.com

Abelacimab trial for AF stopped early due to overwhelming reduction in bleeding

Abelacimab trial for AF stopped early due to overwhelming reduction in bleeding
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Daiichi sankyoErik swainDan bloomfieldLewis dexterMarcs sabatineZora biosciencesByregina schafferJanssen bayerRegeneron pharmaceuticalsSoftcell medicalNovo nordiskJanssen researchBiopharma incBoehringer ingelheimHarvard medical schoolNational blood clot alliance

Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC

Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-toHead Study Comparing a Factor XI Inhibitor to a DOAC

United statesLewis dexterThromb haemostMarcs sabatineDan bloomfieldColl cardiolHarvard medical schoolData monitoring committeeBlackstone life sciencesStudy groupNational blood clot allianceAnthos therapeutics incAnthos therapeuticsDistinguished chairCardiovascular medicineMyocardial infarction

Abelacimab Demonstrates Overwhelming Efficacy vs Rivaroxaban in Phase 2b Trial

Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.

Marcs sabatineDan bloomfieldLewis dexterStudy groupInternational society on thrombosisData monitoring committeeDistinguished chairCardiovascular medicineMyocardial infarctionAnthos therapeuticsNew england journalInternational societyChief medical officerAbelcimab anthos therapeuticsAtrial fibrillation

Upcoming Phase 3 Clinical Program Will Examine Efficacy of Oral PCSK9 Inhibitor MK-0616 in Patients With Hypercholesterolemia

The phase 3 clinical program, CORALreef, consists of 3 trials and is likely the first of its kind for an oral PCSK9 inhibitor, according to the study authors.

Coralreef heLewis dexterMarc sabatineJoerg koglinThrombolysis in myocardial infarction study groupMerck research laboratoriesHarvard medical schoolMyocardial infarction study group

Merck Initiates Phase 3 Clinical program for Oral PCSK9 Inhibitor Candidate MK-0616

RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the initiation of the company s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral.

United statesLewis dexterJoerg koglinMarc sabatineCoralreef heJulie cunninghamHarvard medical schoolExchange commissionMerck co incMerck research laboratoriesStudy groupDistinguished chairCardiovascular medicineLooking statementSecurities litigation reform actAnnual report